Compare MLAB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLAB | BNTC |
|---|---|---|
| Founded | 1982 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.4M | 405.7M |
| IPO Year | N/A | N/A |
| Metric | MLAB | BNTC |
|---|---|---|
| Price | $80.40 | $13.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $83.00 | $28.25 |
| AVG Volume (30 Days) | 104.9K | ★ 253.4K |
| Earning Date | 02-03-2026 | 02-13-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,255,000.00 | N/A |
| Revenue This Year | $4.96 | N/A |
| Revenue Next Year | $5.27 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.39 | N/A |
| 52 Week Low | $55.45 | $9.70 |
| 52 Week High | $155.12 | $17.15 |
| Indicator | MLAB | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 53.02 |
| Support Level | $76.52 | $10.99 |
| Resistance Level | $82.78 | $13.36 |
| Average True Range (ATR) | 2.57 | 0.94 |
| MACD | 0.11 | 0.16 |
| Stochastic Oscillator | 73.53 | 86.72 |
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.